Clearmind Medicine shares are trading higher after the company announced advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval in Hong Kong by the Hong Kong Patent Office.

6/28/24 11:32:05 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CMND alert in real time by email

Get the next $CMND alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$CMND

Date	Price Target	Rating	Analyst

More analyst ratings

$CMND
Press Releases

Fastest customizable press release news feed in the world

View All

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

Vancouver, Canada, April 15, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that its independent Data and Safety Monitoring Board ("DSMB") has completed its review and issued a positive recommendation to continue the ongoing FDA-approved Phase I/IIa clinical trial of CMND-100 for the treatment of Alcohol Use Disorder ("AUD"). The positive DSMB recommendation follows the successful completion of the third cohort and is based

4/15/26 7:30:00 AM ET

$CMND

Biotechnology: Pharmaceutical Preparations

Health Care

Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Vancouver, Canada, April 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD) has met the primary endpoint in its FDA-approved Phase I/IIa clinical trial. Results from the third cohort of the trial indicated a high safety profile for CMND-100, even at the higher dosage administered to dat

4/14/26 7:32:00 AM ET

$CMND

Biotechnology: Pharmaceutical Preparations

Health Care

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Company completed treatment in four additional participate at its Israel clinical site Vancouver, Canada, March 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment and follow-up of 18 participants in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disord

3/30/26 8:32:00 AM ET

$CMND

Biotechnology: Pharmaceutical Preparations

Health Care

$CMND
Leadership Updates

Live Leadership Updates

View All

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Vancouver, Canada, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable Hadassah Medical Center, a leading clinical site in Israel, to join the Company's clinical trial, of which the fir

11/13/25 8:54:39 AM ET

$CMND

Biotechnology: Pharmaceutical Preparations

Health Care

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. In this role, Gifford will lead efforts to strengthen Clearmind's US partnerships, governmental and regulatory advocacy, and strategic alliances in Washington, D.C. and New York, bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines. Prior to joining Cl

10/27/25 9:22:00 AM ET

$CMND

Biotechnology: Pharmaceutical Preparations

Health Care

Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial Tel Aviv, Israel / Vancouver, Canada, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. is pleased to announce that the company has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine, to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 as a potential treatment for Alcohol Use Disorder (AUD). The CM-CMND-001 clinical trial is a multinational, multi-center, single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD su

11/9/23 9:20:00 AM ET

$CMND

Biotechnology: Pharmaceutical Preparations

Health Care

Clearmind Medicine shares are trading higher after the company announced advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval in Hong Kong by the Hong Kong Patent Office.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CMND

Clearmind Medicine shares are trading higher after the company announced advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval in Hong Kong by the Hong Kong Patent Office.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CMND

$CMND
Press Releases

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

$CMND
SEC Filings

SEC Form 6-K filed by Clearmind Medicine Inc.

SEC Form 6-K filed by Clearmind Medicine Inc.

SEC Form 6-K filed by Clearmind Medicine Inc.

$CMND
Leadership Updates

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

$CMND
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Clearmind Medicine Inc.

Clearmind Medicine shares are trading higher after the company announced advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval in Hong Kong by the Hong Kong Patent Office.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $CMND

Clearmind Medicine shares are trading higher after the company announced advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval in Hong Kong by the Hong Kong Patent Office.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $CMND

$CMND Press Releases

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

$CMND SEC Filings

SEC Form 6-K filed by Clearmind Medicine Inc.

SEC Form 6-K filed by Clearmind Medicine Inc.

SEC Form 6-K filed by Clearmind Medicine Inc.

$CMND Leadership Updates

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

$CMND Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Clearmind Medicine Inc.

Recent Analyst Ratings for
$CMND

Recent Analyst Ratings for
$CMND

$CMND
Press Releases

$CMND
SEC Filings

$CMND
Leadership Updates

$CMND
Large Ownership Changes